玻璃酸钠合用塞来昔布治疗膝关节骨性关节炎的疗效

Abstract
Figure/Table
References
Related Citation (8)

Download: PDF (739 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of sodium hyaluronate combined with celecoxib (CSC) on knee osteoarthritis (KOA) and on expressions of cartilage oligomeric matrix protein (COMP) and osteopontin (OPN).Methods A total of 168 patients with KOA treated in Beijing Municipal Corps Hospital between May 2017 and July 2019 were randomly divided into three groups: celecoxib group (oral administration of celecoxib), sodium hyaluronate group (intra-articular injection of sodium hyaluronate) and CSC group (oral administration of celecoxib and intra-articular injection of sodium hyaluronate), with 56 cases in each group. After four weeks of treatment, the differences in overall efficiency, knee joint function, daily life ability (DLA), serum COM and OPN expressions and adverse reactions were evaluated.Results The total effective rate was significantly different between the three groups (P<0.05). It was significantly higher in the CSC group (94.64%) than in the celecoxib group (82.14%) or in the sodium hyaluronate group (78.57%). After four weeks of treatment, the knee functional scores in each of the three groups were significantly higher, especially in the CSC group (P<0.05). After four weeks of treatment, the DLA scores in the three groups were significantly reduced, especially in the CSC group (P<0.05). The levels of serum COMP and OPN in the three groups were significantly reduced after treatment, particularly in the CSC group (P<0.05). There was no significant difference in the incidence of adverse reactions between the three groups (P>0.05).Conclusions The combination of sodium hyaluronate and celecoxib has better curative effect against KOA, which can improve knee function and daily life ability. Its efficacy may be related to the inhibition of serum COMP and OPN expressions.

Key words： knee osteoarthritis sodium hyaluronate celecoxib cartilage oligomeric matrix protein osteopontin

Received: 08 April 2020

ZTFLH:

R684.3

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIANG Hongwei
	ZHAO Baofeng
	ZHANG Tao
	YU Lei
	Ayinuer

Cite this article:

LIANG Hongwei,ZHAO Baofeng,ZHANG Tao等. Effect of combination of sodium hyaluronate and celecoxib on knee osteoarthritis[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2020, 31(10): 865-869.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2020/V31/I10/865

[1]	Carmona-Teres V, Moix-Queralto J, Pujol-Ribera E, et al. Understanding knee osteoarthritis from the patients’ perspective: a qualitative study[J]. BMC Musculoskelet Disord, 2017,18(1):225.
[2]	郑毅, 温晓宏. 关于骨关节炎概念及治疗指南的更新[J]. 中华风湿病学杂志, 2017,21(1):1-3.
[3]	郑晓芬. 骨关节炎发病机制和治疗的最新进展[J]. 中国组织工程研究, 2017, 21(20): 3255-3262.
[4]	Rivera F, Bertignone L, Grandi G, et al. Effectiveness of intra-articular injections of sodium hyaluronate-chondroitin sulfate in knee osteoarthritis: a multicenter prospective study[J]. J Orthop Traumatol, 2016, 17(1): 27-33.
[5]	Das G E, Ng W R, Wong S F, et al. Correlation of serum cartilage oligomeric matrix protein (COMP) and interleukin-16 (IL-16) levels with disease severity in primary knee osteoarthritis: a pilot study in a Malaysian population[J]. PLoS One, 2017,12(9):e184802.
[6]	El D S, Abdelnaby R, Khachab A, et al. Osteopontin as a biochemical marker and severity indicator for idiopathic hip osteoarthritis[J]. Hip Int, 2016, 26(4): 397-403.
[7]	中华医学会风湿病学分会. 骨关节炎诊断及治疗指南[J]. 中华风湿病学杂志, 2010,14(6):416-419.
[8]	Lapane K L, Liu S H, Dubã C E, et al. Factors associated with the use of hyaluronic acid and corticosteroid injections among patients with radiographically confirmed knee osteoarthritis: a retrospective data analysis[J]. Clin Ther, 2017, 39(2): 347-358.
[9]	Michl G L, Katz J N, Losina E. Risk and risk perception of knee osteoarthritis in the US: a population-based study[J]. Osteoarthr Cartilage, 2016,24(4):593-596.
[10]	Hana S, Aicha B T, Selim D, et al. Clinical and radiographic features of knee osteoarthritis of elderly patients[J]. Curr Rheumatol Rev, 2018,14(2):181-187.
[11]	Richards M M, Maxwell J S, Weng L, et al. Intra-articular treatment of knee osteoarthritis: from anti-inflammatories to products of regenerative medicine[J]. Phys Sportsmed, 2016,44(2):101-108.
[12]	Concoff A, Sancheti P, Niazi F, et al. The efficacy of multiple versus single hyaluronic acid injections: a systematic review and meta-analysis[J]. BMC Musculoskelet Disord, 2017,18(1):542.
[13]	Georgiev T, Ivanova M, Kopchev A, et al. Cartilage oligomeric protein, matrix metalloproteinase-3, and Coll2-1 as serum biomarkers in knee osteoarthritis: a cross-sectional study[J]. Rheumatol Int, 2018, 38(5): 821-830.
[14]	Ma T, Zhang Z, Song X, et al. Combined detection of COMP and CS846 biomarkers in experimental rat osteoarthritis: a potential approach for assessment and diagnosis of osteoarthritis[J]. J Orthop Surg Res, 2018, 13(1): 230.
[15]	孙大川,胡春林,孙浩,等. 不同剂量玻璃酸钠注射辅助治疗膝骨关节炎近期疗效评价[J]. 中国药业,2017,26(9):59-62.
[16]	董凯,张芳. 塞来昔布片联合玻璃酸钠注射液治疗膝关节骨性关节炎的临床疗效及安全性[J]. 国际医药卫生导报,2019,25(18):3120-3122.
[17]	Li Y, Xiao W, Sun M, et al. The expression of osteopontin and Wnt5a in articular cartilage of patients with knee osteoarthritis and its correlation with disease severity[J]. Biomed Res Int, 2016, 2016: 9561058.
[18]	Yang Y, Gao S G, Zhang F J, et al. Effects of osteopontin on the expression of IL-6 and IL-8 inflammatory factors in human knee osteoarthritis chondrocytes[J]. Eur Rev Med Pharmacol Sci, 2014,18(23):3580-3586.
[19]	李祺. 洛索洛芬钠片联合关节腔内注射玻璃酸钠治疗骨关节炎的临床研究[J]. 中国临床药理学杂志, 2017,33(15):1421-1424.